The trajectory of Viagra presents a nuanced case for investors in the drug sector. While initially a tremendous success, creating billions, the intellectual property lapse and the subsequent entry of cheaper versions have drastically affected income. This poses questions about the ongoing viability of related drug projects and suggests that just co